OR WAIT null SECS
May 16, 2024
Breyanzi is made from the patient’s own T cells, which are genetically reengineered into CAR-T cells and then delivered through infusion as a one-time treatment.
The company presented results from its programs for Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.
May 14, 2024
One of the first planned areas of focus is the field of preterm birth-associated early onset respiratory disease.
May 10, 2024
Regeneron’s work in CAR-T cell therapy development includes engineering receptor architecture to improve CAR-T cell sensitivity and improve immune response.
May 08, 2024
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.
May 06, 2024
The collaboration will target solid tumors using Poseida’s allogeneic CAR-T platform to develop convertibleCAR programs.
May 03, 2024
Mariana’s portfolio of radioligand therapies will strengthen Novartis’ radioligand therapy pipeline.
April 30, 2024
Shanghai Henlius Biotech’s first biosimilar has previously received approvals by the European Commission and National Medical Products Administration.
April 26, 2024
Beqvez (fidanacogene elaparvovec-dzkt), a one-time gene therapy, helps adults with hemophilia B produce factor IX themselves instead of receiving regular intravenous infusions.